Conclusion not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for the active ingredient omalizumab (ATC code according to WHO: R03DX05) - 473851

World Biggest Tenders Source

This tender with title Conclusion not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for the active ingredient omalizumab (ATC code according to WHO: R03DX05) - 473851 has been published on Bidding Source portal dated 13 Jul 2026 for the country of Germany. It has been categorized on Pharmaceutical products. For similar tenders you can see tenders mentioned below of this page.

General Information

Germany

Tender Title :

Conclusion not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for the active ingredient omalizumab (ATC code according to WHO: R03DX05) - 473851

Tender Type :

Invitation for Bids

Reference No. :

473851

Country :

Germany

Publish Date :

13 Jul 2026

Closing Date :

30 Sep 2027

Notice Language :

English

Tender Categories (CPVs) :

Pharmaceutical products

Full Tender Details :

For viewing full details of tenders, you should Log in to your account. If not registered yet, Please Register Now

Or Request a call back now and one of our representatives will contact you. Contact us

Similar Tenders

Generic tender for Ticagrelor - 472012 Germany Conclusion of non-exclusive discount agreements pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the aforementioned active ingredients, with the option of concluding such agreements within the framework of the so-called open-house procedure. - 473529 Germany Open House Biologics Discount Agreements 2025-07 - Follitropin delta - 474600 Germany Open House Biologics Discount Agreements 2026-27 - Follitropin delta - 474331 Germany Conclusion not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for drugs with the trade name Orylmyte(R) (ATC code according to WHO: V01AA03) - 477816 Germany Conclusion not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for drugs with the trade name Oralair(R) (ATC code according to WHO: V01AA02) - 477144 Germany Agreement not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for the active ingredient ipratropium bromide (ATC code according to WHO: R03BB01) - 478099 Germany Awarded - Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient axitinib, ATC L01EK01, for the period 01.09.2025 - 31.08.2027 (plus extension option of 1 x 12 months) - 459923 Germany Awarded - Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient etravirine, ATC J05AG04, for the period 01.07.2024 - 30.06.2026 - 459153 Germany Awarded - Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient Ixekizumab, ATC L04AC13, for the period 01.07.2024 - 30.06.2026 - 459071 Germany

Conclusion not excluding drug discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for the active ingredient omalizumab (ATC code according to WHO: R03DX05) - 473851

General Information

Germany

Similar Tenders

Pharmaceutical products Tenders

Germany Tenders

Europe Tenders

Tenders

info@biddingsource.com